Login / Signup

Cost-effectiveness analysis of axicabtagene ciloleucel vs. salvage chemotherapy for relapsed or refractory adult diffuse large B-cell lymphoma in China.

Na LiBin ZhengHongfu CaiTing YangYunda HongMaobai LiuJian-da Hu
Published in: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2022)
At its current price, Axi-Cel is not likely to be a cost-effective option compared to salvage chemotherapy for adult patients with R/R DLBCL.
Keyphrases
  • diffuse large b cell lymphoma
  • epstein barr virus
  • locally advanced
  • squamous cell carcinoma
  • rectal cancer
  • chemotherapy induced
  • acute lymphoblastic leukemia
  • acute myeloid leukemia
  • young adults